Brief Summary
This study is testing a new medicine, SNV4818, for people with advancedat a late stage, far along cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Intervention / Treatment
- Drug: SNV4818
- Drug: Fulvestrant
Inclusion Criteria:
- Advanced or metastatic solid tumor with an activating PIK3CA mutation.
- Refractory to or intolerant of available therapies
- Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in bloodthe red bodily fluid that transports oxygen and other nutrients around the body.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1